UNDERSTAND THE TOTAL MARKET SIZE AND TREATMENT OPPORTUNITIES FOR BIOMARKERS
The development of biomarker-driven therapies continues to be a major trend in oncology. As biomarkers are often clinically relevant in more than one indication, the concept of sizing eligible patient populations is evolving. With DRG Biomarker Epidemiology data and insights, the entire biomarker-defined population can be sized in minutes.
|Renal Cell Carinoma||x|
|Non-Small-Cell Lung Cancer||x||x||x|
|Head and Neck Cancer||x|
|Small-Cell Lung Cancer||x|
|Source: Decision Resources Group|
EPIDEMIOLOGY IS THE FOUNDATION OF MARKET FORECASTING AT ALL PHASES OF PRODUCT DEVELOPMENT AND STRATEGY
You need biomarker epidemiology data you can trust in order to:
- Complete biomarker-driven market sizing assessments based on patient population sizes and patient flows.
- Build the foundation of a market forecast for strategic planning for biomarker-targeting for new and existing assets.
- Understand how the patient populations for certain biomarkers will evolve over time.
- Answer any question you may have about specific subpopulations, biomarkers, and the impact of new studies.
DRG BIOMARKER EPIDEMIOLOGY REPORTS
DRG Epidemiology has created a robust repository of the prevalence of biomarker and mutation-defined treatment-eligible cancer populations. With DRG’s Biomarker Epidemiology you can now save months of time and resources researching each individual tumor in which a biomarker may be significant. Quickly access data on biomarker patient population sizes, based on diverse eligibility criteria and treatment settings.
In addition to an extensive literature review and modeling, we leverage our in-house estimates of cancer incidence for solid and hematological malignancies. All our estimates are rigorously researched and transparently reported.
- Patient Flow Diagrams
- Customizable populations and data visualization dashboards
- Testing rates and companion diagnostic information
- Real world data augmentation
- Patient journey and demographic characteristics
- Real world analysis of associated comorbidities and treatments
- RAS - Epidemiology - Mature Markets Data
- Key Findings
- Diagnosed Incidence of RAS-Mutated Tumors per 100,000 People (all ages) in 2018 and 2038
- Analysis of the Diagnosed Incidence of RAS-Mutated Tumors in 2018 by Site
- Patient-Flow Diagram for RAS-Mutated Tumors in 2018
- Epidemiology Data
- RAS-Mutated Diagnosed Incident Cases
- RAS-Mutant Diagnosed Colorectal Cancer Incident Cases
- RAS-Mutant Diagnosed NSCLC Incident Cases
- KRAS-Mutant Diagnosed Pancreatic Cancer Incident Cases
- Diagnosed 1st Line Drug-Treatable Population
- Diagnosed 1st Line Colorectal Cancer Drug-Treatable Population
- Diagnosed 1st Line NSCLC Drug-Treatable Population
- Diagnosed 1st Line Pancreatic Cancer Drug-Treatable Population
- Reference Materials
- Literature Review
- Studies Included in the Analysis of the Prevalence of RAS-Mutated NSCLC, Colorectal, and Pancreatic Cancers
- Studies Excluded from the Analysis of the Prevalence of RAS-Mutated NSCLC, Colorectal, and Pancreatic Cancers
- Risk/Protective Factors
- Literature Review
Author(s): Narendra Parihar
Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.
His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.